Financial Review of ImmunoCellular Therapeutics, Ltd. (AMEX:IMUC)


Quarterly Sales and EPS Roundup:

ImmunoCellular Therapeutics, Ltd. (IMUC) reported 1 number of analysts estimated the mean sale of 1.2 million. The analysts estimated sales for the higher end at 1.2 million and lower end at 1.2 million.

1 number of analysts have estimated the sales of the company for the quarter ending Aug 24, 2017- Aug 25, 2017, analysts estimated mean sale target of 2.4 million while high and low sale targets are estimated at 2.4 million and 2.4 million respectively.

ImmunoCellular Therapeutics, Ltd. (IMUC) reported earning per shares for the quarter ending Nov 13 AMC at -1.36, whereas, 1 number of analysts estimated the mean EPS at -0.56. The analysts estimated EPS for the higher end at -0.56 and lower end at -0.56 while the year ago reported earnings per share was 0.

The company has mean EPS estimate of -3.83 reported by 1 number of analyst for the quarter ending Current Qtr.(Mar2017). The analysts estimated mean EPS at -3.83 while the high and low EPS estimate stand at -3.83 and -3.83 respectively. In contrast to the year ago quarter EPS was at -7.2. EPS long term mean growth rate estimated by analysts is at 13.86%, whereas, the high and low Long term growth rate estimated at 16.24.

Valuation Ratios of ImmunoCellular Therapeutics, Ltd. (IMUC) versus the Industry and Sector:

Let’s have a look at some of the important valuation ratios of the ImmunoCellular Therapeutics, Ltd. (IMUC). These ratios are important while doing valuation of the company or the shares of the company.

ImmunoCellular Therapeutics, Ltd. (IMUC) currently the company’s industry has 13.86 P/E and the sector P/E is 16.24. The industry’s and sector’s  high P/E for the past year is 113.68 and 31.67 respectively and low P/E ratio for the last 5 years is 6.78 for the industry and 10.26 for the Sector.

Beta is also an important valuation ratio for analyzing the stock of the company, IMUC has its industry and Sector’s beta remains at 0.9 and 0.77 respectively.

The industry and sector ratio of Price to Cash Flow ticked at 7.64 and 9.99 respectively.

5 Year Growth Rate Analysis:

Growth rates are very important while analyzing the long term growth and valuation of a certain company.

5 year sales growth rate is an important factor for valuation analysis, the industry’s and the sector’s growth for next 5 years ticked at -2.36 and -8.01 respectively.

ImmunoCellular Therapeutics, Ltd. (IMUC) Trading Statistics:

The company declined -0.19% and closed its last trading session at $0.37. The market capitalization of the company is at $5.71 Million. The stock touched 52-week High of $4.58 on 10/24/16 and 52-week Low of $0.25 on 08/11/17. The stock currently has Weekly Volatility of 16.95% and Monthly Volatility of 12.93%. The Beta for the company stands at 1 and its Average True Range (ATR) shows a value of 0.04.